Tome Biosciences Acquires Replace Therapeutics

Intellia Therapeutics Acquires Rewrite Therapeutics

February 3, 2022

Biotechnology

Intellia Therapeutics has acquired Rewrite Therapeutics, a UC Berkeley–spawned startup developing DNA-writing genome editing technologies. The deal includes $45 million upfront and up to $155 million in research and regulatory milestones, expanding Intellia's in-house editing capabilities to potentially enable new precision editing strategies.

Taconic Biosciences Acquires TransCure bioServices

January 20, 2026

Biotechnology

Taconic Biosciences has acquired TransCure bioServices SAS to create an integrated global translational research platform combining Taconic's genetically engineered and humanized mouse models with TransCure's preclinical in vivo services. The deal expands Taconic's capabilities across oncology, immunology, infectious disease, and advanced modalities while preserving TransCure's brand and operational structure to ensure continuity for employees and clients.

Tesis Biosciences Acquires Genome Explorations

February 16, 2022

Biotechnology

Tesis Biosciences has acquired Genome Explorations to accelerate its clinical research and product development efforts in targeted genetic sequencing and precision medicine. The acquisition brings Genome Explorations’ genomic profiling and molecular diagnostics capabilities and clinical research staff into Tesis’ integrated platform to speed development of proprietary therapeutics and diagnostic products.

Twist Bioscience Acquires iGenomX

June 30, 2021

Biotechnology

Twist Bioscience acquired iGenomX, a developer of high-throughput multiplex NGS library preparation tools, to expand its NGS workflow capabilities and accelerate customer conversion from microarray genotyping to sequencing-based genotyping. The deal consideration was $35 million (combination of cash and Twist stock, plus up to $5 million contingent stock), and Twist expects modest near-term financial impact with incremental revenue from the acquired business in fiscal 2023.

Ginkgo Bioworks Acquires Patch Biosciences

February 28, 2024

Biotechnology

Ginkgo Bioworks has acquired Patch Biosciences, a startup that built an AI platform for sequence design to advance genetic medicines. The acquisition will integrate Patch's machine‑learning models and validated assays into Ginkgo's platform to expand its gene therapy, cell therapy and RNA therapeutics capabilities for biopharma customers.

Charles River Laboratories Acquires Vigene Biosciences

May 17, 2021

Biotechnology

Charles River Laboratories agreed to acquire Vigene Biosciences, a Rockville, Maryland-based gene therapy CDMO, for $292.5 million in cash plus up to $57.5 million in contingent payments. The acquisition expands Charles River's cell and gene therapy contract development and manufacturing capabilities—adding CGMP viral vector and plasmid DNA production—and is expected to close in early Q3 2021.